Consider interventions aimed at modifying risk factors in order to delay or prevent the onset of acute heart failure, including:[1]McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726.
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
http://www.ncbi.nlm.nih.gov/pubmed/34447992?tool=bestpractice.com
Coronary artery disease: manage with aspirin, beta-blockers, statins, and ACE inhibitors, as needed
Optimising treatment of hypertension, smoking cessation, and lipid control provides substantial benefit in patients with coronary artery disease.[1]McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726.
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
http://www.ncbi.nlm.nih.gov/pubmed/34447992?tool=bestpractice.com
Optimal control of hypertension often requires more than one antihypertensive medication.[23]Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023 Dec 1;41(12):1874-2071.
https://journals.lww.com/jhypertension/fulltext/2023/12000/2023_esh_guidelines_for_the_management_of_arterial.2.aspx
http://www.ncbi.nlm.nih.gov/pubmed/37345492?tool=bestpractice.com
Different antihypertensive drugs (diuretics, ACE inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers) have been shown to be effective, especially in older people, both with and without a history of myocardial infarction.[1]McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726.
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
http://www.ncbi.nlm.nih.gov/pubmed/34447992?tool=bestpractice.com
Diabetes mellitus: in addition to metabolic control, ensure aggressive control of lipids and blood pressure.[24]Yusuf S, Sleight P, Pogue J, et al; the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000 Jan 20;342(3):145-53.
http://www.nejm.org/doi/full/10.1056/NEJM200001203420301#t=article
http://www.ncbi.nlm.nih.gov/pubmed/10639539?tool=bestpractice.com
Use sodium-glucose cotransporter 2 (SGLT2) inhibitors (e.g., dapagliflozin or empagliflozin) for patients with type 2 diabetes and either established cardiovascular disease or at high cardiovascular risk to prevent hospitalisations for heart failure, irrespective of whether they have an existing heart failure diagnosis (HFpEF or HFrEF).[1]McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726.
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
http://www.ncbi.nlm.nih.gov/pubmed/34447992?tool=bestpractice.com
[2]Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022 May 3;145(18):e895-1032.
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000001063
http://www.ncbi.nlm.nih.gov/pubmed/35363499?tool=bestpractice.com
Patients with diabetes taking SGLT2 inhibitors are at increased risk of developing diabetic ketoacidosis (including euglycaemic ketoacidosis).[25]Musso G, Saba F, Cassader M, et al. Diabetic ketoacidosis with SGLT2 inhibitors. BMJ. 2020 Nov 12;371:m4147.
https://www.doi.org/10.1136/bmj.m4147
http://www.ncbi.nlm.nih.gov/pubmed/33184044?tool=bestpractice.com
Alcohol consumption and excessive salt and fluid intake: discourage in patients with known left ventricular dysfunction.[1]McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726.
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
http://www.ncbi.nlm.nih.gov/pubmed/34447992?tool=bestpractice.com
Drugs that can cause or potentiate heart failure: avoid, if safe and possible to do so.[26]Page RL, O'Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016 Aug 9;134(6):e32-69.
http://circ.ahajournals.org/content/134/6/e32.long
http://www.ncbi.nlm.nih.gov/pubmed/27400984?tool=bestpractice.com
All patients with heart failure are recommended to have pneumococcal, COVID-19 and annual influenza vaccination.[1]McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726.
https://academic.oup.com/eurheartj/article/42/36/3599/6358045
http://www.ncbi.nlm.nih.gov/pubmed/34447992?tool=bestpractice.com
[87]Girerd N, Chapet N, Roubille C, et al. Vaccination for respiratory infections in patients with heart failure. J Clin Med. 2021 Sep 22;10(19):4311.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8509310
http://www.ncbi.nlm.nih.gov/pubmed/34640328?tool=bestpractice.com